Relationship Between Metabolic DysfunctionAssociated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers

被引:0
|
作者
Rossi, Felipe A. Munoz [1 ]
Agudelo, Juanita Salazar [2 ]
Castro, Nestor Israel Quinapanta [3 ]
Mosquera, Sofia Z. [2 ]
Fajardo, Maria Clara Mejia [4 ]
Lopez, Edgar Dario Mosquera [5 ]
Olarte, Jonathan Dany Espitia [1 ]
Medina, Maria Andrea Figueroa [6 ]
Simancas, Edwin Zuniga [7 ]
Osuna, Luis Fernando Saldarriaga [8 ]
机构
[1] Univ Nacl Colombia, Internal Med, Bogota, Colombia
[2] CES Clin, Emergency Med, Medellin, Colombia
[3] Reg Autonomous Univ Andes, Res & Biostat, Ambato, Ecuador
[4] Cooperat Univ Colombia, Gen Med, Medellin, Colombia
[5] Univ Cent Ecuador, Gen Med, Quito, Ecuador
[6] Libre Univ Colombia, Gen Med, Barranquilla, Colombia
[7] Sinu Univ, Cardiovasc & Metab Ctr, Gen Clin Caribbean, Blas Lezo Clin,Internal Med, Cartagena, Colombia
[8] Univ Nacl Colombia, Bogota, Colombia
关键词
non-alcoholic fatty liver disease; gamma glutamyl transferase (ggt); nash and steatosis; high-density lipoproteins (hdl-c); lipoprotein (a); INSULIN-RESISTANCE; RISK; STEATOHEPATITIS; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.7759/cureus.63019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic dysfunction -associated steatotic liver disease (MASLD) primarily affects the adult population and is closely related to obesity. The most severe form of MASLD, metabolic dysfunctionassociated steatohepatitis (MASH), can progress to liver fibrosis. While lipoprotein(a) (Lp(a)) is known to be associated with cardiovascular disease, its relationship with MASLD remains unclear. This study aims to determine the prevalence of MASLD in ambulatory patients and to explore the association between Lp(a) levels and advanced liver damage. Methods: This retrospective cross-sectional study included 130 patients older than 18 years seen in a healthcare center in Medellin, Colombia, between April 2023 and May 2024. Sociodemographic, clinical, and specific biomarker data were collected. Patients with cirrhosis, previous liver disease, frequent alcohol consumption, cancer, and other severe conditions were excluded. Continuous variables were analyzed using Student's t -tests or Mann -Whitney tests according to their distribution, and categorical variables were analyzed using contingency tables and chi-square tests. Results: Of the 130 patients, 57.9% (n=73) had MASLD, with a higher prevalence in patients with obesity (80%, n=32). Lp(a) levels were abnormally high in 43.1% (n=31) of patients; however, a weak but significant inverse correlation was found between Lp(a) levels and the Fibrosis -4 (FIB -4) score, which is used to assess the severity of liver fibrosis. Patients with MASLD had significantly lower high -density lipoprotein (HDL) and vitamin D levels, and higher levels of gamma-glutamyl transferase (GGT). Conclusions: This study highlights the significant prevalence of MASLD in outpatients and its relationship with various biomarkers, including Lp(a), HDL, vitamin D, and GGT. Although the findings suggest a possible utility of Lp(a) as a biomarker in MASLD, longitudinal studies are needed to confirm these associations and clarify their role in liver disease progression. The study's limitations include its cross-sectional nature and potential selection bias, indicating the need for further research to validate these results.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Sarcopenia and metabolic dysfunction-associated steatotic liver disease: The role of exercise-related biomarkers
    Al-Nimer, Marwan S.
    WORLD JOURNAL OF HEPATOLOGY, 2025, 17 (02)
  • [32] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [33] USEFULNESS OF SERUM MICRORNAS AS BIOMARKERS FOR PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Blakley, Caroline
    Nelson, Benjamin
    Qarooni, Shatha
    Lee, Wai Han
    Tryggestad, Jeanie
    Short, Kevin
    Palle, Sirish Kumar
    HEPATOLOGY, 2024, 80 : S626 - S626
  • [34] ASSOCIATION BETWEEN CARDIOVASCULAR HEALTH AND METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Alebna, Pamela L.
    Yasin, Alhussain
    Harley, Kayla
    Ambrosio, Matthew
    Dixon, Dave L.
    Siddiqui, Mohammad
    Salloum, Fadi N.
    Mehta, Anurag
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2029 - 2029
  • [35] Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Moon, Sang Yi
    Son, Minkook
    Cho, Jung-Hwan
    Kim, Hye In
    Han, Ji Min
    Bae, Ji Cheol
    Suh, Sunghwan
    THYROID, 2025, 35 (01) : 79 - 86
  • [36] Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease
    Yang, Dandan
    Dai, Hongsheng
    Wang, Yulu
    Zhang, Jiayi
    Wei, Min
    Shan, Ming
    Zhang, Xiaoqian
    FRONTIERS IN NUTRITION, 2025, 12
  • [37] Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Malik, Adnan
    Javaid, Sadia
    Malik, Muhammad Imran
    Qureshi, Shahbaz
    ANNALS OF HEPATOLOGY, 2024, 29 (06)
  • [38] Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella
    Noureddin, Mazen
    Wei, Lai
    Castera, Laurent
    Tsochatzis, Emmanuel A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (01) : 9 - 11
  • [39] The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States
    Li, Zhongtao
    Guo, Hao
    He, Hongyu
    Wang, Shu
    Pei, Shufen
    Xie, Liang
    PLOS ONE, 2025, 20 (04):
  • [40] MASHing up molecular imaging and biomarkers for improved diagnosis of metabolic dysfunction-associated steatotic liver disease
    Fagoonee, Sharmila
    Panella, Riccardo
    MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH, 2024, 36 (04): : 169 - 171